Elanilam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Targeting exon 1 with brazosiran for the Huntington's disease transcriptome.
Elanilam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Targeting exon 1 with brazosiran for the Huntington's disease transcriptome.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in